Case Report: Familial partial lipodystrophy, description of novel and ultrarare variants with distinct phenotypic spectrum
Abstract
Familial partial lipodystrophy (FPLD) is a rare inherited disorder characterized by selective loss of subcutaneous fat and severe metabolic complications. Eight subtypes of FPLD have been described to date, most of which are caused by variants in genes involved in adipocyte differentiation and lipid metabolism. The most common form, FPLD type 2, is caused by heterozygous variants in the LMNA gene, whereas much rarer forms, such as FPLD type 6, are associated with biallelic variants in LIPE. Here, we describe five patients carrying novel or ultrarare pathogenic variants in LMNA (p.Lys117Arg, p.Asn195Tyr, p.Ser239Arg, p.Lys515Glu) and LIPE (homozygous p.Val1068GlyfsTer102), thereby expanding the known genetic and phenotypic spectrum of FPLD. All individuals exhibited abnormal fat distribution and metabolic disturbances, with considerable interindividual variability in the extent and pattern of adipose tissue loss and accumulation. LMNA-related cases showed cardiac involvement, whereas the LIPE-related case presented peculiar patterns of fat redistribution and specific clinical features. These findings underscore the importance of genetic testing in patients with otherwise unexplained lipodystrophy to facilitate early diagnosis, guide personalized management, enable family screening, and support long-term multidisciplinary follow-up for monitoring metabolic, cardiovascular, and systemic complications.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.